Eusol Biotech

Eusol Biotech, established in 2005, adheres to the philosophy of sustainable management and is dedicated to investing in the development of innovative new drugs to fulfill unmet medical needs in neurological diseases and injuries. It specializes in the development of sleep aids that repair spinal cord and peripheral nerve injuries, as well as treat sleep disorders, in order to improve the quality of life. Eusol Biotech’s pipeline product ES135 (rhFGF1) is a recombinant human acidic fibroblast growth factor that has been patented in Taiwan, EU, the United States, and China. A multicenter phase III clinical trial for spinal cord injury is ongoing in Taiwan. In addition, a phase III clinical trial for SM-1, a 3-in-1 capsule sleep aid, has been completed in the U.S.